A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to d-amfetamine, methylphenidate and modafinil

Lisdexamfetamine dimesylate, which consists of l-lysine covalently bound to d-amfetamine, is the first prodrug for treating ADHD. Its metabolic conversion to yield d-amfetamine by rate-limited, enzymatic hydrolysis is unusual because it is performed by peptidases associated with red blood cells. Oth...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropharmacology 2013-10, Vol.73, p.348-358
Hauptverfasser: Heal, David J., Buckley, Niki W., Gosden, Jane, Slater, Nigel, France, Charles P., Hackett, David
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 358
container_issue
container_start_page 348
container_title Neuropharmacology
container_volume 73
creator Heal, David J.
Buckley, Niki W.
Gosden, Jane
Slater, Nigel
France, Charles P.
Hackett, David
description Lisdexamfetamine dimesylate, which consists of l-lysine covalently bound to d-amfetamine, is the first prodrug for treating ADHD. Its metabolic conversion to yield d-amfetamine by rate-limited, enzymatic hydrolysis is unusual because it is performed by peptidases associated with red blood cells. Other stimulants shown to be effective in managing ADHD include d-amfetamine, methylphenidate and modafinil. All have the potential for misuse or recreational abuse. The discriminative and reinforcing effects of these compounds were determined in rats using a 2-choice, d-amfetamine (0.5 mg/kg, i.p.)-cued drug-discrimination test, and by substitution for intravenous cocaine in self-administration. Lisdexamfetamine (0.5–1.5 mg/kg [d-amfetamine base], p.o.) generalised to saline when tested 15 min post-dosing, but dose-dependently generalised to d-amfetamine at 60 min. At 120 min, its d-amfetamine-like effects were substantially diminished. At 15 min, methylphenidate (3.0–10 mg/kg, p.o.) and d-amfetamine (0.1–1.5 mg/kg, p.o.) dose-dependently generalised to the intraperitoneal d-amfetamine cue. Switching to the intraperitoneal route reduced the interval required for lisdexamfetamine to be recognised as d-amfetamine-like, but did not alter its potency. Switching to intraperitoneal injection increased the potency of methylphenidate and d-amfetamine by 3.4× and 2.2×, respectively. Modafinil (50–200 mg/kg, i.p.) generalised partially, but not fully, to d-amfetamine. Methylphenidate (0.1, 0.3, 1.0 mg/kg/injection, i.v.) maintained robust self-administration at the 2 highest doses. Neither lisdexamfetamine (0.05, 0.15 or 0.5 mg/kg/injection [d-amfetamine base], i.v.) nor modafinil (0.166, 0.498 or 1.66 mg/kg/injection, i.v.) served as reinforcers. The results reveal important differences between the profiles of these stimulants. Lisdexamfetamine did not serve as a positive reinforcer in cocaine-trained rats, and although it generalised fully to d-amfetamine, its discriminative effects were markedly influenced by its unusual pharmacokinetics. •Discriminative and reinforcing effects of lisdexamfetamine (LDX) determined in rats.•LDX's unusual pharmacokinetics influence its ability to generalise to d-amfetamine.•LDX does not serve as a positive reinforcer in cocaine-trained rats.•LDX profiled against d-amfetamine, methylphenidate and modafinil.
doi_str_mv 10.1016/j.neuropharm.2013.05.021
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1500764770</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0028390813002359</els_id><sourcerecordid>1430852412</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-a834d9402ea8d0af9b18d1d4917c159e087cb52039e33bf96df14446b4ac68823</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi0EotvCKyAfOZAwjp3EOZaqUKRKXOBsOfaE9Sqxg-2s6KvwtHi1hR57Gsnz__945iOEMqgZsO7jofa4xbDudVzqBhivoa2hYS_IjsmeVz104iXZATSy4gPIC3KZ0gEAhGTyNbloeC8kDN2O_Lmma0QzO--Mnike9bzp7IKnYaJ5j9S6ZKJbnC-vR6TaWxrR-SlE4_zPYg4rxuwwnQyzSxZ_62XCrIsFqfPUhGXV0aUSmQO11VP3A10w7x_mdY_eWZ3P6Uuweirfmd-QV5OeE759rFfkx-fb7zd31f23L19vru8rI3qeKy25sIOABrW0oKdhZNIyKwbWG9YOCLI3Y9sAH5DzcRo6OzEhRDcKbTopG35F3p9zyy6_NkxZLWVnnGftMWxJsRag70Tfw_NSwUG2jWCnVHmWmhhSijiptZxRxwfFQJ0gqoN6gqhOEBW0qkAs1nePU7ZxQfvf-I9aEXw6C7Cc5egwqmQceoPWFZZZ2eCen_IXH3q2tw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1430852412</pqid></control><display><type>article</type><title>A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to d-amfetamine, methylphenidate and modafinil</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Heal, David J. ; Buckley, Niki W. ; Gosden, Jane ; Slater, Nigel ; France, Charles P. ; Hackett, David</creator><creatorcontrib>Heal, David J. ; Buckley, Niki W. ; Gosden, Jane ; Slater, Nigel ; France, Charles P. ; Hackett, David</creatorcontrib><description>Lisdexamfetamine dimesylate, which consists of l-lysine covalently bound to d-amfetamine, is the first prodrug for treating ADHD. Its metabolic conversion to yield d-amfetamine by rate-limited, enzymatic hydrolysis is unusual because it is performed by peptidases associated with red blood cells. Other stimulants shown to be effective in managing ADHD include d-amfetamine, methylphenidate and modafinil. All have the potential for misuse or recreational abuse. The discriminative and reinforcing effects of these compounds were determined in rats using a 2-choice, d-amfetamine (0.5 mg/kg, i.p.)-cued drug-discrimination test, and by substitution for intravenous cocaine in self-administration. Lisdexamfetamine (0.5–1.5 mg/kg [d-amfetamine base], p.o.) generalised to saline when tested 15 min post-dosing, but dose-dependently generalised to d-amfetamine at 60 min. At 120 min, its d-amfetamine-like effects were substantially diminished. At 15 min, methylphenidate (3.0–10 mg/kg, p.o.) and d-amfetamine (0.1–1.5 mg/kg, p.o.) dose-dependently generalised to the intraperitoneal d-amfetamine cue. Switching to the intraperitoneal route reduced the interval required for lisdexamfetamine to be recognised as d-amfetamine-like, but did not alter its potency. Switching to intraperitoneal injection increased the potency of methylphenidate and d-amfetamine by 3.4× and 2.2×, respectively. Modafinil (50–200 mg/kg, i.p.) generalised partially, but not fully, to d-amfetamine. Methylphenidate (0.1, 0.3, 1.0 mg/kg/injection, i.v.) maintained robust self-administration at the 2 highest doses. Neither lisdexamfetamine (0.05, 0.15 or 0.5 mg/kg/injection [d-amfetamine base], i.v.) nor modafinil (0.166, 0.498 or 1.66 mg/kg/injection, i.v.) served as reinforcers. The results reveal important differences between the profiles of these stimulants. Lisdexamfetamine did not serve as a positive reinforcer in cocaine-trained rats, and although it generalised fully to d-amfetamine, its discriminative effects were markedly influenced by its unusual pharmacokinetics. •Discriminative and reinforcing effects of lisdexamfetamine (LDX) determined in rats.•LDX's unusual pharmacokinetics influence its ability to generalise to d-amfetamine.•LDX does not serve as a positive reinforcer in cocaine-trained rats.•LDX profiled against d-amfetamine, methylphenidate and modafinil.</description><identifier>ISSN: 0028-3908</identifier><identifier>EISSN: 1873-7064</identifier><identifier>DOI: 10.1016/j.neuropharm.2013.05.021</identifier><identifier>PMID: 23748096</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Benzhydryl Compounds - pharmacology ; Cocaine ; Cocaine - pharmacology ; d-Amfetamine ; Dextroamphetamine - pharmacology ; Discrimination (Psychology) - drug effects ; Discriminative effects ; Dose-Response Relationship, Drug ; Drug discrimination ; Drug Evaluation, Preclinical ; Female ; Lisdexamfetamine ; Lisdexamfetamine Dimesylate ; Methylphenidate ; Methylphenidate - pharmacology ; Modafinil ; Rats ; Reinforcement (Psychology) ; Reinforcer ; Self Administration</subject><ispartof>Neuropharmacology, 2013-10, Vol.73, p.348-358</ispartof><rights>2013 Elsevier Ltd</rights><rights>Copyright © 2013 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-a834d9402ea8d0af9b18d1d4917c159e087cb52039e33bf96df14446b4ac68823</citedby><cites>FETCH-LOGICAL-c473t-a834d9402ea8d0af9b18d1d4917c159e087cb52039e33bf96df14446b4ac68823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.neuropharm.2013.05.021$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23748096$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Heal, David J.</creatorcontrib><creatorcontrib>Buckley, Niki W.</creatorcontrib><creatorcontrib>Gosden, Jane</creatorcontrib><creatorcontrib>Slater, Nigel</creatorcontrib><creatorcontrib>France, Charles P.</creatorcontrib><creatorcontrib>Hackett, David</creatorcontrib><title>A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to d-amfetamine, methylphenidate and modafinil</title><title>Neuropharmacology</title><addtitle>Neuropharmacology</addtitle><description>Lisdexamfetamine dimesylate, which consists of l-lysine covalently bound to d-amfetamine, is the first prodrug for treating ADHD. Its metabolic conversion to yield d-amfetamine by rate-limited, enzymatic hydrolysis is unusual because it is performed by peptidases associated with red blood cells. Other stimulants shown to be effective in managing ADHD include d-amfetamine, methylphenidate and modafinil. All have the potential for misuse or recreational abuse. The discriminative and reinforcing effects of these compounds were determined in rats using a 2-choice, d-amfetamine (0.5 mg/kg, i.p.)-cued drug-discrimination test, and by substitution for intravenous cocaine in self-administration. Lisdexamfetamine (0.5–1.5 mg/kg [d-amfetamine base], p.o.) generalised to saline when tested 15 min post-dosing, but dose-dependently generalised to d-amfetamine at 60 min. At 120 min, its d-amfetamine-like effects were substantially diminished. At 15 min, methylphenidate (3.0–10 mg/kg, p.o.) and d-amfetamine (0.1–1.5 mg/kg, p.o.) dose-dependently generalised to the intraperitoneal d-amfetamine cue. Switching to the intraperitoneal route reduced the interval required for lisdexamfetamine to be recognised as d-amfetamine-like, but did not alter its potency. Switching to intraperitoneal injection increased the potency of methylphenidate and d-amfetamine by 3.4× and 2.2×, respectively. Modafinil (50–200 mg/kg, i.p.) generalised partially, but not fully, to d-amfetamine. Methylphenidate (0.1, 0.3, 1.0 mg/kg/injection, i.v.) maintained robust self-administration at the 2 highest doses. Neither lisdexamfetamine (0.05, 0.15 or 0.5 mg/kg/injection [d-amfetamine base], i.v.) nor modafinil (0.166, 0.498 or 1.66 mg/kg/injection, i.v.) served as reinforcers. The results reveal important differences between the profiles of these stimulants. Lisdexamfetamine did not serve as a positive reinforcer in cocaine-trained rats, and although it generalised fully to d-amfetamine, its discriminative effects were markedly influenced by its unusual pharmacokinetics. •Discriminative and reinforcing effects of lisdexamfetamine (LDX) determined in rats.•LDX's unusual pharmacokinetics influence its ability to generalise to d-amfetamine.•LDX does not serve as a positive reinforcer in cocaine-trained rats.•LDX profiled against d-amfetamine, methylphenidate and modafinil.</description><subject>Animals</subject><subject>Benzhydryl Compounds - pharmacology</subject><subject>Cocaine</subject><subject>Cocaine - pharmacology</subject><subject>d-Amfetamine</subject><subject>Dextroamphetamine - pharmacology</subject><subject>Discrimination (Psychology) - drug effects</subject><subject>Discriminative effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug discrimination</subject><subject>Drug Evaluation, Preclinical</subject><subject>Female</subject><subject>Lisdexamfetamine</subject><subject>Lisdexamfetamine Dimesylate</subject><subject>Methylphenidate</subject><subject>Methylphenidate - pharmacology</subject><subject>Modafinil</subject><subject>Rats</subject><subject>Reinforcement (Psychology)</subject><subject>Reinforcer</subject><subject>Self Administration</subject><issn>0028-3908</issn><issn>1873-7064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1DAQhi0EotvCKyAfOZAwjp3EOZaqUKRKXOBsOfaE9Sqxg-2s6KvwtHi1hR57Gsnz__945iOEMqgZsO7jofa4xbDudVzqBhivoa2hYS_IjsmeVz104iXZATSy4gPIC3KZ0gEAhGTyNbloeC8kDN2O_Lmma0QzO--Mnike9bzp7IKnYaJ5j9S6ZKJbnC-vR6TaWxrR-SlE4_zPYg4rxuwwnQyzSxZ_62XCrIsFqfPUhGXV0aUSmQO11VP3A10w7x_mdY_eWZ3P6Uuweirfmd-QV5OeE759rFfkx-fb7zd31f23L19vru8rI3qeKy25sIOABrW0oKdhZNIyKwbWG9YOCLI3Y9sAH5DzcRo6OzEhRDcKbTopG35F3p9zyy6_NkxZLWVnnGftMWxJsRag70Tfw_NSwUG2jWCnVHmWmhhSijiptZxRxwfFQJ0gqoN6gqhOEBW0qkAs1nePU7ZxQfvf-I9aEXw6C7Cc5egwqmQceoPWFZZZ2eCen_IXH3q2tw</recordid><startdate>20131001</startdate><enddate>20131001</enddate><creator>Heal, David J.</creator><creator>Buckley, Niki W.</creator><creator>Gosden, Jane</creator><creator>Slater, Nigel</creator><creator>France, Charles P.</creator><creator>Hackett, David</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20131001</creationdate><title>A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to d-amfetamine, methylphenidate and modafinil</title><author>Heal, David J. ; Buckley, Niki W. ; Gosden, Jane ; Slater, Nigel ; France, Charles P. ; Hackett, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-a834d9402ea8d0af9b18d1d4917c159e087cb52039e33bf96df14446b4ac68823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Benzhydryl Compounds - pharmacology</topic><topic>Cocaine</topic><topic>Cocaine - pharmacology</topic><topic>d-Amfetamine</topic><topic>Dextroamphetamine - pharmacology</topic><topic>Discrimination (Psychology) - drug effects</topic><topic>Discriminative effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug discrimination</topic><topic>Drug Evaluation, Preclinical</topic><topic>Female</topic><topic>Lisdexamfetamine</topic><topic>Lisdexamfetamine Dimesylate</topic><topic>Methylphenidate</topic><topic>Methylphenidate - pharmacology</topic><topic>Modafinil</topic><topic>Rats</topic><topic>Reinforcement (Psychology)</topic><topic>Reinforcer</topic><topic>Self Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Heal, David J.</creatorcontrib><creatorcontrib>Buckley, Niki W.</creatorcontrib><creatorcontrib>Gosden, Jane</creatorcontrib><creatorcontrib>Slater, Nigel</creatorcontrib><creatorcontrib>France, Charles P.</creatorcontrib><creatorcontrib>Hackett, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Heal, David J.</au><au>Buckley, Niki W.</au><au>Gosden, Jane</au><au>Slater, Nigel</au><au>France, Charles P.</au><au>Hackett, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to d-amfetamine, methylphenidate and modafinil</atitle><jtitle>Neuropharmacology</jtitle><addtitle>Neuropharmacology</addtitle><date>2013-10-01</date><risdate>2013</risdate><volume>73</volume><spage>348</spage><epage>358</epage><pages>348-358</pages><issn>0028-3908</issn><eissn>1873-7064</eissn><abstract>Lisdexamfetamine dimesylate, which consists of l-lysine covalently bound to d-amfetamine, is the first prodrug for treating ADHD. Its metabolic conversion to yield d-amfetamine by rate-limited, enzymatic hydrolysis is unusual because it is performed by peptidases associated with red blood cells. Other stimulants shown to be effective in managing ADHD include d-amfetamine, methylphenidate and modafinil. All have the potential for misuse or recreational abuse. The discriminative and reinforcing effects of these compounds were determined in rats using a 2-choice, d-amfetamine (0.5 mg/kg, i.p.)-cued drug-discrimination test, and by substitution for intravenous cocaine in self-administration. Lisdexamfetamine (0.5–1.5 mg/kg [d-amfetamine base], p.o.) generalised to saline when tested 15 min post-dosing, but dose-dependently generalised to d-amfetamine at 60 min. At 120 min, its d-amfetamine-like effects were substantially diminished. At 15 min, methylphenidate (3.0–10 mg/kg, p.o.) and d-amfetamine (0.1–1.5 mg/kg, p.o.) dose-dependently generalised to the intraperitoneal d-amfetamine cue. Switching to the intraperitoneal route reduced the interval required for lisdexamfetamine to be recognised as d-amfetamine-like, but did not alter its potency. Switching to intraperitoneal injection increased the potency of methylphenidate and d-amfetamine by 3.4× and 2.2×, respectively. Modafinil (50–200 mg/kg, i.p.) generalised partially, but not fully, to d-amfetamine. Methylphenidate (0.1, 0.3, 1.0 mg/kg/injection, i.v.) maintained robust self-administration at the 2 highest doses. Neither lisdexamfetamine (0.05, 0.15 or 0.5 mg/kg/injection [d-amfetamine base], i.v.) nor modafinil (0.166, 0.498 or 1.66 mg/kg/injection, i.v.) served as reinforcers. The results reveal important differences between the profiles of these stimulants. Lisdexamfetamine did not serve as a positive reinforcer in cocaine-trained rats, and although it generalised fully to d-amfetamine, its discriminative effects were markedly influenced by its unusual pharmacokinetics. •Discriminative and reinforcing effects of lisdexamfetamine (LDX) determined in rats.•LDX's unusual pharmacokinetics influence its ability to generalise to d-amfetamine.•LDX does not serve as a positive reinforcer in cocaine-trained rats.•LDX profiled against d-amfetamine, methylphenidate and modafinil.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>23748096</pmid><doi>10.1016/j.neuropharm.2013.05.021</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0028-3908
ispartof Neuropharmacology, 2013-10, Vol.73, p.348-358
issn 0028-3908
1873-7064
language eng
recordid cdi_proquest_miscellaneous_1500764770
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Animals
Benzhydryl Compounds - pharmacology
Cocaine
Cocaine - pharmacology
d-Amfetamine
Dextroamphetamine - pharmacology
Discrimination (Psychology) - drug effects
Discriminative effects
Dose-Response Relationship, Drug
Drug discrimination
Drug Evaluation, Preclinical
Female
Lisdexamfetamine
Lisdexamfetamine Dimesylate
Methylphenidate
Methylphenidate - pharmacology
Modafinil
Rats
Reinforcement (Psychology)
Reinforcer
Self Administration
title A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to d-amfetamine, methylphenidate and modafinil
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T17%3A06%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20preclinical%20evaluation%20of%20the%20discriminative%20and%20reinforcing%20properties%20of%20lisdexamfetamine%20in%20comparison%20to%20d-amfetamine,%20methylphenidate%20and%20modafinil&rft.jtitle=Neuropharmacology&rft.au=Heal,%20David%20J.&rft.date=2013-10-01&rft.volume=73&rft.spage=348&rft.epage=358&rft.pages=348-358&rft.issn=0028-3908&rft.eissn=1873-7064&rft_id=info:doi/10.1016/j.neuropharm.2013.05.021&rft_dat=%3Cproquest_cross%3E1430852412%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1430852412&rft_id=info:pmid/23748096&rft_els_id=S0028390813002359&rfr_iscdi=true